Intervacc AB (publ)
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more
Market Cap & Net Worth: Intervacc AB (publ) (2E9)
Intervacc AB (publ) (F:2E9) has a market capitalization of $5.88 Million (€5.73 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #32574 globally and #3646 in its home market, demonstrating a 28.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intervacc AB (publ)'s stock price €0.02 by its total outstanding shares 340813188 (340.81 Million).
Intervacc AB (publ) Market Cap History: 2026 to 2026
Intervacc AB (publ)'s market capitalization history from 2026 to 2026. Data shows growth from $5.88 Million to $5.88 Million (0.00% CAGR).
Intervacc AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intervacc AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2E9 by Market Capitalization
Companies near Intervacc AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Intervacc AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Intervacc AB (publ) Historical Marketcap From 2026 to 2026
Between 2026 and today, Intervacc AB (publ)'s market cap moved from $5.88 Million to $ 5.88 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.88 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Intervacc AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.88 Million USD |
| MoneyControl | $5.88 Million USD |
| MarketWatch | $5.88 Million USD |
| marketcap.company | $5.88 Million USD |
| Reuters | $5.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.